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Abstract
Drug resistance and tumor heterogeneity are formidable challenges in cancer medicine, which is particularly relevant
for KRAS-mutant cancers, the epitome of malignant tumors recalcitrant to targeted therapy efforts and ﬁrst-line
chemotherapy. In this study, we delineate that KRAS-mutant lung cancer cells resistant to pemetrexed (MTA) and anti-
MEK drug trametinib acquire an exquisite dependency on endoplasmic reticulum (ER) stress signaling, rendering
resistant cancer cells selectively susceptible to blockage of HSP90, the receptor tyrosine kinase AXL, the eukaryotic
translation initiation factor 4E (eIF4E), and the unfolded protein response (UPR). Mechanistically, acquisition of drug
resistance enables KRAS-mutant lung cancer cells to bypass canonical KRAS effectors but entail hyperactive AXL/eIF4E,
increased protein turnover in the ER, and adaptive activation of an ER stress-relief UPR survival pathway whose
integrity is maintained by HSP90. Notably, the unique dependency and sensitivity induced by drug resistance are
applicable to KRAS-mutant lung cancer cells undergoing de novo intratumor heterogeneity. In line with these ﬁndings,
HSP90 inhibitors synergistically enhance antitumor effects of MTA and trametinib, validating a rational combination
strategy to treat KRAS-mutant lung cancer. Collectively, these results uncover collateral vulnerabilities co-occurring
with drug resistance and tumor heterogeneity, informing novel therapeutic avenues for KRAS-mutant lung cancer.
Introduction
Resistance to therapeutics and tumor heterogeneity
inevitably limit clinical efﬁcacy of cancer treatment, which
is particularly relevant for KRAS-mutant cancers that are
the most common type of human malignancies deﬁned by
genetic alterations and, ironically, the largest subset of
tumors that cannot be effectively targeted by currently
available therapeutics1. Oncogenic mutant KRAS is
associated with striking heterogeneity2, heightened
resistance to ﬁrst-line chemotherapy3,4, and has proven
difﬁcult to pharmacologically target directly5, as have
attempts to block synthetic lethal interactions with a
mutant KRAS allele that have met with only limited
success6.
Innovative efforts to inhibit KRAS-dependent tumor
growth by extinguishing KRAS downstream signaling
pathways have led to the important observation that
suppressing the mitogen-activated protein kinase (MAPK)
cascade RAF/MEK/ERK is necessary but insufﬁcient7.
Consequently, highly selective RAF, MEK, and ERK
inhibitors only show marginal antitumor activity in KRAS-
mutant tumors8. A major cause for the inefﬁciency of
MAPK inhibitors, such as the clinically approved anti-
MEK drug trametinib9, is the rapid and inevitable
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development of resistant diseases. The transient or short-
lived nature of trametinib has been attributed to
treatment-induced repression of negative feedback loops
that reactivates the MAPK pathway via various compen-
satory mechanisms10–13. Nevertheless, albeit improved
effects of MEK inhibitors by blocking compensatory
MAPK reactivation, resistant tumors on the combination
treatment still evolve14, suggesting the existence of other
uncharacterized mechanisms of adaptive resistance.
In this study, we investigated the molecular mechanisms
underlying adaptive resistance to currently available can-
cer drugs in KRAS-mutant lung cancer. We showed that
HSP90/AXL/eIF4E-regulated endoplasmic reticulum (ER)
stress response, or the unfolded protein response (UPR),
represents an acquired dependency and confers a selective
vulnerability in drug-resistant KRAS-mutant lung cancer
cells that drug-naïve parental cells lack. We further
demonstrated that this collateral sensitivity induced by
drug resistance also applies to KRAS-mutant lung cancer
cells that have undergone de novo intratumor hetero-
geneity. These results uncover tumor vulnerabilities that
can be therapeutically exploited to overcome drug resis-
tance and tumor heterogeneity, providing a new rationale
for combination therapies to combat aggressive and
difﬁcult-to-treat KRAS-mutant lung cancer.
Results
A shared mechanism of resistance to MTA and trametinib
in KRAS-mutant lung cancer
To delineate cellular and molecular mechanisms that
underpin drug resistance in KRAS-mutant lung cancer, we
modeled adaptive resistance by step-wisely and chroni-
cally treating A549 and H358 cells with chemotherapy
drug pemetrexed (MTA) whereby resistant populations
(A549R and H358R) persisted after the treatment. A549R
and H358R cells showed cross-resistance to trametinib,
indicating a shared mechanism of resistance to the two
cancer drugs (Supplementary Fig. 1A–C). Drug-resistant
A549R and H358R underwent profound changes in E-
Cadherin or/and Vimentin compared to the parental cells
(Supplementary Fig. 1A–C), which is characteristic of cell
state switch through an epithelial-to-mesenchymal tran-
sition (EMT). Alike, de novo enforcement of mesenchy-
mal reprogramming by treating A549 and H358 with
transforming growth factor (TGF-β1) that fueled ded-
ifferentiated subpopulations (A549_EMT, H358_EMT)
co-opted acquired resistance to MTA and trametinib
(Supplementary Fig. 1D, E). Supporting our results, ana-
lyzing transcriptomic data of KRAS-mutant cancer cells2
and matched tumors (pre- and post-treatment with BRAF
and MEK inhibitors) from patients with BRAF-mutant
melanoma15 revealed that EMT gene signatures are sig-
niﬁcantly enriched in KRAS-mutant cancer cells resistant
to KRAS suppression (KRAS-independent) and in residual
melanoma tumors refractory to and recurrent after
MAPK (BRAF+MEK) inhibition (Fig. 1a, b). Importantly,
the KRAS-mutant cancer cells independent of KRAS
function, driven by mesenchymal reprogramming (high
EMT gene signatures)2,16, exhibited signiﬁcantly greater
resistance to various MEK inhibitors (Fig. 1c). Mining the
data from The Cancer Genome Atlas (TCGA) showed
that EMT is positively correlated with tumor progression
and predicts poor prognosis in KRAS-mutant lung cancer
(Supplementary Fig. 1F, G). These results underscore the
clinical relevance of our experimental models and
uncover a common principle through which KRAS-
mutant lung cancer cells acquire resistance to MTA and
trametinib.
HSP90 dictates adaptive resistance to MTA and trametinib
in KRAS-mutant lung cancer cells
To identify cellular processes that represent selective
dependencies of drug-resistant cells, we performed drug
screening using small molecules targeting various path-
ways (Supplementary Table 1). Among the compounds
tested, only onalespib and R428, inhibitors of the mole-
cular chaperone HSP90 and the receptor tyrosine kinase
(RTK) AXL, differentially impaired the resistant versus
parental cells, causing over 10- and 3-fold reduction of the
half-maximal inhibitory concentration (IC50) in A549R
compared to A549, respectively (Fig. 1d, e; Supplementary
Fig. 2A, B). In contrast, other compounds, including
inhibitors of the RTKs (FGFR, EGFR) and KRAS effectors
(PI3K, STAT3) previously reported to mediate resistance
to MEK inhibitors12,17–20 showed no differential effect on
A549R and A549. Similarly, PU-WS13, a selective inhi-
bitor of the ER-resident HSP90 isoform GRP94 (ref. 21),
was equal for A549R and A549 (Supplementary Fig. 2A),
indicating that the selective effect of onalespib on A549R
is due to the inhibition of the cytosolic HSP90. Further
analyses using other HSP90 inhibitors (luminespib,
ganetespib) and drug-resistant cells (A549_EMT, H358R,
and H358_EMT) led to similar ﬁndings (Fig. 1f; Supple-
mentary Fig. 2B–G).
HSP90 is moderately overexpressed in drug-resistant
relative to parental cells, but HSP90 inhibition with ona-
lespib (0.5 µM) selectively induced apoptosis in resistant
cells only, marked by dramatic increase of cleaved poly
(ADP-ribose) polymerase (Cl PARP) and caspase 7 (Cl
Cas7) at 24 h (Fig. 1g; Supplementary Figs. 2E and 3A).
Notably, onalespib blocked EMT in A549 and H358 cells,
evidenced by upregulated E-Cad and non-phospho-
β-catenin, but failed to do so in drug-resistant cells (Fig.
1g; Supplementary Figs. 2E and 3A), indicating that an
intact HSP90 is essential for drug-resistant mesenchymal
cell state. In agreement, the EMT gene signature is a
biomarker that positively determines the sensitivity of
KRAS-mutant and pan-solid cancer cells to various
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HSP90 inhibitors (Fig. 1h, i) and high levels of HSP90AA1
(HSP90) are associated with tumor progression, poor
survival, and high recurrence rates in KRAS-mutant and
pan-cancers (Fig. 1j; Supplementary Fig. 3B–E). These
results identify HSP90 as a particular dependency of
KRAS-mutant lung cancer cells acquiring resistance to
MTA and trametinib.
Hyperactive AXL/eIF4E deﬁnes drug-resistant KRAS-mutant
lung cancer cells
Next, we investigated signaling events that underlie
HSP90 requirement in drug-resistant KRAS-mutant lung
cancer cells. A549R and A549 cells displayed similar basal
activities in RAF/MEK/ERK and PI3K/AKT/mTOR path-
ways, as were the cells treated with onalespib (Supple-
mentary Fig. 3F), matching the results of drug screening
using inhibitors of these pathways (Supplementary Fig.
2A). In contrast, the drug-resistant cells (A549R, H358R,
and H358_EMT) overexpressed MYC (also known as c-
MYC), MNK1 (MAP kinase-interacting serine/threonine-
protein kinase 1), and eIF4E, and showed overwhelming
phosphorylation (activation) in AXL (p-AXL), MNK1 (p-
MNK1), and eIF4E (p-eIF4E). However, onalespib
(0.5 µM) acutely reduced AXL, MYC, and p-eIF4E whereas
the total eIF4E was not affected, as did R428 (Fig. 2a, b;
Supplementary Fig. 3A). Notably, like onalespib, R428
induced apoptosis (Cl Cas7) in A549R only, whereas it
blocked EMT by inducing a mesenchymal-to-epithelial
transition (MET) in A549 (Fig. 2b). This effect was faith-
fully translated to an increased toxicity of R428 on drug-
resistant cells (Fig. 2c). In agreement with other stu-
dies22,23, we demonstrated that AXL complexed with
HSP90 (Supplementary Fig. 4A) and that AXL gene and
protein levels were positively correlated with EMT (Sup-
plementary Fig. 4B–D). Importantly, the AXL mRNA level
is a predictive marker for poor prognosis in lung cancer
patients (Supplementary Fig. 4E, F).
Small-molecule inhibitors of MYC (JQ-1), MNK1
(CGP57380), and eIF4E/eIF4G complex (4EGI-1) more
strongly suppressed the resistant than parental cells (Fig.
2d–g), as did MYC and EIF4E knockdown that barely
affected cell proliferation but markedly reduced resistance
to MTA and trametinib and augmented the sensitivity to
onalespib (Fig. 2h–j; Supplementary Fig. 4G). Further, the
MYC expression is positively associated with AXL, EIF4E,
and EMT signatures (Supplementary Fig. 4H) and both
mRNA and protein levels of the EIF4E are of prognostic
signiﬁcance in KRAS-mutant lung cancer, lung adeno-
carcinoma, and lung cancer (Fig. 2k; Supplementary Fig.
5A–C). These data, in line with a positive role for eIF4E in
EMT24, establish AXL/MYC/eIF4E as central signaling
nodes required for adaptive resistance in KRAS-mutant
lung cancer cells.
Deregulation of AXL/eIF4E activates an ER stress-relief UPR
survival mechanism
To dissect the effector pathways downstream of AXL/
MYC/eIF4E signaling, we conducted an integrative analysis
of TCGA data, which signiﬁcantly linked eIF4E to ER-
related functions (Supplementary Fig. 5D–F). We therefore
reasoned that deregulation of AXL/eIF4E induces ER stress
and activates an ER stress-responsive mechanism. Indeed,
The EMT status and AXL expression were signiﬁcantly
correlated with the UPR gene signature (Supplementary Fig.
5G, H). Importantly, compared to parental cells, A549R
showed a higher magnitude of protein secretion (Fig. 3a),
upregulated expression of UPR genes [HSPA5 (GRP78/BiP),
EIF2AK3 (PERK), ERN1 (IRE1α), and ATF4 (ATF4)] (Fig.
3b), increased levels of ER chaperons (BiP, Calnexin, and
PDI), ER stress sensors (ATF6, IRE1α, and PERK), and UPR
effectors (p-JNK and p-ATF2) (Fig. 3c). In sharp contrast,
eIF2α and CHOP that catalyze a malfunctional UPR and
induce apoptosis25,26 were repressed in A549R (Fig. 3c).
Consequently, further perturbations of ER homeostasis by
(see ﬁgure on previous page)
Fig. 1 HSP90 inhibitors selectively target KRAS-mutant lung cancer cells resistant to chemo and anti-MEK drugs. a, b Gene set enrichment
analysis (GSEA) of KRAS-mutant cancer cell lines (a) and matched tumor samples (pre- and post-treatment with MAPK (BRAF+MEK) inhibitors of
patients with BRAF-mutant melanoma (b) revealed signiﬁcant enrichment of EMT gene signatures in KRAS-independent cell lines (a) and in residual
melanoma resistant to and recurrent after MAPK inhibition (b). The Gene Expression Omnibus (GEO) dataset GSE15126 (a) and GSE65185 (b) were
used for GSEA. c Mesenchymal phenotype is inversely associated with sensitivity to MEK inhibitors in KRAS-mutant cancer cell lines. Dichotomization
of epithelial and mesenchymal subgroups is based on an EMT gene signature deﬁned by the GSE15126 dataset. *p < 0.05, **p < 0.01. d, e
Dose–response curves (d) and clonogenic assay (e) of A549R (mesenchymal) and A549 (epithelial) cells using the HSP90 inhibitor onalespib. The half-
maximal inhibitory concentration (IC50) is shown to the right (d). ****p < 0.0001, unpaired two-sided t-test. f Dose–response curves (left) and
clonogenic assay (right) of mesenchymal (H358R, H358_EMT) and parental H358 cells using the HSP90 inhibitor onalespib. g Immunoblots of A549
and A549R cells treated with onalespib (0.5 µM) for the indicated time. h, i Association of the sensitivity to HSP90 inhibitors with mesenchymal cell
states in lung adenocarcinoma (h) and solid cancer cell lines (i). Gene expression data and IC50 values are downloaded from the Cancer Cell Line
Encyclopedia and the Genomics of Drug Sensitivity in Cancer, respectively. Dichotomization of IC50_low and IC50_high is based on the median IC50
value. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. j Kaplan–Meier analysis of KRAS-mutant lung cancer based on HSP90AA1 expression. Patients
with high- (in red) or low-HSP90AA1 (in black) were stratiﬁed by optimal cutoff value of the HSP90AA1 across all patients using the surv_cutpoint
function in the R “maxstat” package. Overall survival and cumulative hazard rates are analyzed and plotted using the R “survival” and “survminer”
package. The p value is calculated by the log-rank test
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treating with tunicamycin, MG-132, and thapsigargin that
induce persistent ER stress preferentially impaired A549R
(Fig. 3d; Supplementary Fig. 6A). Importantly, A549R and
H358R were particularly susceptible to inhibitors of PERK
(GSK2656157), JNK (JNK-IN-8, SP600125), but not of IREα
(4µ8c), p38 (LY2228820), or eIF2α (Salubrinal), compared to
the parental cells (Fig. 3e–g; Supplementary Fig. 6B). Genetic
depletion of PERK reduced p-ATF2 and re-sensitized A549R
cells to MTA and trametinib (Fig. 3h, i), whereas it induced
an MET in A549 cells (Supplementary Fig. 6C). In line with
these results, analyzing gene ontology terms and TCGA data
signiﬁcantly associated ATF2 with EMT, PERK with ATF2
and JNK but not with MAPK14 (p38) in KRAS-mutant lung
cancer (Supplementary Fig. 6D–F).
R428 strikingly increased p-eIF2α and CHOP on top of
the induction of apoptosis (cleaved caspase 7), indicating
that hyperactive AXL/eIF4E signaling is functionally
important for PERK/JNK/ATF2-dependent UPR (Fig. 2b).
Similarly, EIF4E knockdown perturbed the UPR by sub-
stantially inducing p-ATF2 and p-eIF2α (Fig. 2h). Thus,
deregulation of AXL/eIF4E in drug-resistant cancer cells
invokes ER stress, which in turn activates a stress-relief
UPR mediated by the PERK/JNK/ATF2 cascade.
HSP90 controls PERK/JNK/ATF2 integrity and protects from
a malfunctional UPR
Next, we sought evidence that connects PERK/JNK/
ATF2-dependent UPR with HSP90. Blocking HSP90
function with onalespib profoundly interfered with ER
stress responses, measured by dramatic decrease of the
PERK and IREα protein levels27 (Fig. 3c), and marked
inhibition of the HSP90/PERK complex formation (Fig. 3j)
in A549R cells. Notably, onalespib treatment enormously
upregulated ER stress-induced UPR genes (Supplemen-
tary Fig. 7A) and pro-apoptotic UPR effectors (p-eIF2α
and CHOP) at 24 h (Fig. 3c), a time coincident with the
induction of apoptotic markers (Cl PARP, Cl Cas7)
(Fig. 1g). These results indicate that an intact HSP90 is
critical for PERK/JNK/ATF2-dependent UPR that is pro-
survival and that HSP90 blockage tips the balance from
survival towards apoptosis by turning on a malfunctional
UPR25,26 executed by the eIF2α/CHOP axis. In agreement,
the UPR gene signature is signiﬁcantly correlated with
unfavorable clinical outcomes in patients with lung and
pan-cancers (Supplementary Fig. 7B–E).
HSP90/AXL/eIF4E-regulated UPR regulates de novo
intratumor heterogeneity of KRAS-mutant lung cancer cells
Our models recapitulate tumor progression upon can-
cer drugs, which might differ from that occurring under
pathological circumstances such as de novo intratumor
heterogeneity. A549 cells displayed marked hetero-
geneity28–30, evidenced by coexistence of epithelial
(holoclone) and mesenchymal (paraclone) subpopulations
under standard culture conditions (Supplementary Fig.
8A). Transcriptomic proﬁling of the A549 holoclone and
paraclone30 revealed overexpression of epithelial [CDH1
(E-Cadherin), TJP3 (tight junction protein ZO-3),
CLDN4/7 (epithelial tight junction proteins Claudin 4/7)],
and mesenchymal (SNAI2, ZEB2 and VIM) markers,
respectively. Notably, numerous genes encoding key
components of the resistance pathway, most prominently
GAS6 [encoding growth arrest-speciﬁc protein 6 (GAS-6),
a cognate ligand of AXL], AXL (AXL), MKNK1 (MNK1),
HSP90AA1, and HSP90AB1 that encode the cytosolic
isoforms HSP90α and HSP90β, respectively, were
expressed at signiﬁcantly higher levels in A549 paraclones
than the holoclone (Fig. 3k). Importantly, the A549
paraclone that displayed heightened resistance to MTA
and MEK inhibitors (trametinib, PD0325901) was highly
susceptible to inhibitors of AXL, eIF4E, JNK, and HSP90
compared to the A549 holoclone (Fig. 3l–n). Thus,
HSP90/AXL/eIF4E-regulated UPR that underpins adap-
tive resistance to MTA and trametinib also regulates
intratumor heterogeneity of KRAS-mutant lung tumor
cells that occurs under pathological conditions, extra-
polating our ﬁndings to a generalized principle that gov-
erns tumor progression (Fig. 4a).
(see ﬁgure on previous page)
Fig. 3 AXL/eIF4E-regulated ER stress-relief UPR underpins drug resistance and intratumor heterogeneity in KRAS-mutant lung cancer. a
A549 and A549R cells without or with brefeldin A (5 µg/ml) treatment (6 h) are proﬁled for secreted proteins. Shown are representative data of three
independent experiments (n= 3). b Transcriptional quantiﬁcation of UPR genes in A549R and A549 cells by qRT-PCR. c Immunoblots of A549 and
A549R cells treated onalespib (0.5 µM) for the indicated time. d–g Dose–response curves to tunicamycin (d), MG-132 (d), and inhibitors to PERK and
JNK (e–g) assayed on resistant (A549R, H358R) versus parental (A549, H358) cells. Representative results of clonogenic assays are shown to the right.
h, i A549R cells transfected with PERK-speciﬁc and control siRNAs were subjected to immunoblotting (h) and dose–responsive curves to pemetrexed
and trametinib (i). Growth curves of the transfected cells are also shown (h). j Protein lysates (200 μg) prepared from A549R cells treated with
onalespib or vehicle were subjected to coimmunoprecipitation with HSP90 and PERK antibodies. Proteins in the precipitates (IP) and the starting
material (input) were visualized by western blotting. k Volcano plots of transcriptomic proﬁling (RNAseq) of the A549_holo and A549_para clones.
The X-axis is the fold-change (log2) of individual genes in the holoclone versus paraclone. Genes signiﬁcantly downregulated (adjusted p value <0.05)
in the holo compared to paraclones are shown in green and genes signiﬁcantly upregulated in the A549_holo versus A549_para are marked in red.
Note that HSP90AA1 and HSP90AB1 (encoding HSP90) and the genes involved in EMT, AXL signaling, and the UPR are enriched in the A549_para
clone. l–n Dose–response curves to MTA and the MEK inhibitors PD0325901 and trametinib (l), inhibitors of AXL, eIF4E, and JNK (m) and HSP90 (n) as
determined on A549_holo_clone (black) and A549_para_clone (red) subpopulations. Data are mean ± s.d. of three biological replicates (n= 3)
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HSP90 blockage enhances antitumor effects of MTA and
trametinib in lung cancer models
Our ﬁnding that HSP90/AXL/eIF4E-regulated UPR
fosters tumor evolution and heterogeneity provides a
conceptual framework for developing rational therapeutic
strategies to treat KRAS-mutant lung cancer. As proof of
concept, we tested if antagonizing HSP90 enhances anti-
tumor effects of MTA and trametinib. Onalespib strongly
synergized with trametinib and MTA in inhibiting the
proliferation of KRAS-mutant A549, H358, and murine
KP cells but not of KRAS wild-type H3122 and PC9 cells
(Fig. 4b; Supplementary Fig. 8B, C). Consistently, short-
term exposure (24 h) to the combined treatment with
trametinib and onalespib dramatically suppressed A549
and H358 cell growth to a much greater extent than single
drug alone (Fig. 4c). Ex vivo organotypic culture and
treatment (24 h) of patient-derived xenograft (PDX)
tumors revealed that MTA activated the adaptive resis-
tance mechanism, gauged by marked increase of MYC, p-
eIF4E, and p-ATF2, which, however, was effectively
counteracted by addition of onalespib (Fig. 4d). In
agreement, analyzing transcriptomic data from previous
studies2,15 revealed that the UPR gene signature was sig-
niﬁcantly enriched in KRAS-mutant cancer cells that
underwent an EMT and acquired KRAS independence
(Fig. 4e) and in residual BRAF-mutant melanoma resistant
to and relapsed after the concurrent treatment with BRAF
and MEK inhibitors (Fig. 4f). These results underscore the
ability of MAPK inhibitors to activate the UPR in pre-
clinical models and cancer patients.
Finally, we assessed in vivo efﬁcacy of the combined
treatment with trametinib and onalespib, both of which
were administrated at doses signiﬁcantly below clini-
cally achievable levels9,31. The combination showed
potent antitumor effects in H358 xenografts and a PDX
model of KRAS-mutant lung cancer without apparent
toxicities (Fig. 4g, h; Supplementary Fig. 8D). Impor-
tantly, residual tumors after the combination therapy
showed augmented apoptosis (Cl Cas3) and reduced
proliferation (Ki-67), accompanied by marked
attenuation of adaptive properties, e.g., mesenchymal
phenotypes (ZEB1), compared to those treated with
trametinib alone (Fig. 4i; Supplementary Fig. 8E). These
results interrogate our in vitro and ex vivo results and
the clinical data of patients, emphasizing the impor-
tance to investigate and harness acquired dependency
(collateral sensitivity) resulting from tumor evolution
and heterogeneity to treat KRAS-mutant lung cancer
and perhaps other malignancies as well.
Discussion
In this study, we uncovered that AXL/eIF4E-regulated
UPR signaling network, with HSP90 at the helm of the
regulatory hierarchy, is an acquired dependency of and
confers a selective vulnerability in KRAS-mutant lung
cancer cells resistant to chemo and anti-MEK cancer
drugs. This non-genetic mechanism, unprecedented for
MTA resistance31 and different from previously reported
ones that contribute to adaptive resistance to MEK inhi-
bitors10–12,17–20, is clinically relevant in that it under-
pinned KRAS-independent survival of KRAS-mutant
cancer cells and was activated in patients’ tumors that had
acquired resistance to MEK inhibitors. Notably, this col-
lateral sensitivity induced by drug resistance is also
applicable to KRAS-mutant lung cancer cells that have
undergone intratumor heterogeneity under pathological
circumstances. Therefore, pharmacological and/or genetic
blockage of key nodes of the HSP90/AXL/eIF4E/UPR
signaling cascade selectively induces apoptotic cell death
of drug-resistant cancer cells, limits tumor heterogeneity
(see ﬁgure on previous page)
Fig. 4 HSP90 antagonism enhances antitumor effects of MTA and trametinib in preclinical cancer models. a Schematic overview of acquired
vulnerabilities resulting from drug resistance. Epi epithelial cell state, Mes mesenchymal cell state. b Growth inhibition of KRAS-mutant murine (KP1)
and human (A549, H358) lung adenocarcinoma cell lines after treated with trametinib, MTA, and onalespib, alone or in combinations. Each drug was
dosed at the indicated concentrations for single treatment or mixed following threefold serial dilutions for combination treatment. Data are mean ±
s.d. of three biological replicates (n= 3). Plots of fraction affected (Fa) versus combination index (CI) was determined by the CompuSyn software. CI <
1 indicates synergism. c HSP90 inhibition enhances trametinib effectiveness by preventing adaptive drug resistance. H358 and A549 cells treated
(24 h) with onalespib and trametinib, alone or in combination, were washed with PBS and subjected to further culture for additional 10 days in the
absence of the drug. d Immunoblots of a lung adenocarcinoma patient (patient 1)-derived xenograft tumors cultured ex vivo and treated with
vehicle, pemetrexed (1 µM), and onalespib (0.5 µM), alone or in combination for 24 h. e, f GSEA of KRAS-mutant cancer cell lines (e) and matched
tumor samples (pre- and post-treatment with MAPK inhibitors) of patients with BRAF-mutant melanoma (f) show signiﬁcant enrichment of UPR gene
signatures in KRAS-independent cell lines (e) and in residual melanoma that survived BRAF inhibitors (f). The GEO dataset GSE15126 and GSE65185
were used for the analysis. g, h Volumes of H358 xenografts (g) and a KRAS-mutant lung cancer patient (patient 2)-derived xenograft model (h)
treated with vehicle or the indicated drugs. *p < 0.05, **p < 0.01, ****p < 0.0001 by two-way ANOVA. Tumor weights at the end of the treatment are
shown to the right. *p < 0.05, **p < 0.01, ****p < 0.0001 by unpaired two-sided t-test. i Immunohistochemistry (IHC) analysis for EMT (ZEB1) and
apoptosis (Cl caspase 3) in H358 xenograft tumors after treated with the indicated drugs. Original overall magniﬁcation ×100 (scale bar: 200 μM).
Images were taken and processed using CaseViewer software. Both the original IHC slides and the corresponding slides with gradient map
visualization were shown. Blue: insigniﬁcant (background); green: moderate signiﬁcant; yellow: signiﬁcant; orange: more signiﬁcant; red: most
signiﬁcant
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in vitro, and precludes the emergence of adaptive phe-
notypes in vivo.
Our results provide a strong rationale for combining
current chemo and anti-MEK cancer drugs with inhi-
bitors of the HSP90/AXL/eIF4E/UPR pathway to treat
KRAS-mutant lung cancer and perhaps other malig-
nancies for which no effective therapy available for
advanced diseases. As preclinical proof of concept, drug
combinations of clinically advanced HSP90 inhibitors32
with trametinib or MTA potently suppressed cancer
cell viability and tumor growth in various tumor mod-
els, including a PDX model of KRAS-mutant lung
adenocarcinoma, validating a long-sought and readily
implemented therapy for the most devastating subset of
lung cancer. It is also conceivable that HSP90/AXL/
eIF4E signaling strength, ER stress magnitudes, and
UPR status may stratify subsets of patients with KRAS-
mutant lung cancer who likely beneﬁt from the com-
bination therapy.
Materials and methods
Cell culture and compounds
KRAS-mutant (A549, H358) and KRAS wild-type
(H3122 and PC9) lung cancer cell lines were obtained
from American Type Culture Collection (ATCC, Mana-
ssas, VA, USA). Murine KRASG12D; p53−/− cells (KP)
were derived from a murine lung adenocarcinoma gen-
erated as previously described33. Cells were cultured in
RPMI-1640 (Sigma-Aldrich, St. Louis, MO, USA), sup-
plemented with 10% fetal bovine seurm (FBS) (Life
Technologies, Grand Island, NY, USA) and 1% penicillin/
streptomycin (Sigma-Aldrich) at 37 °C in a humid incu-
bator with 5% CO2. All cell lines were authenticated by
DNA ﬁngerprinting and negative for mycoplasma. Che-
mical inhibitors used in this study, including those tar-
geting AXL34, MYC35, eIF4E36,37, and PERK38, are listed
in Supplementary Table 1.
In vitro modeling of drug resistance
Drug-resistant populations (A549R and H358R) were
generated by chronical treatment (6 months) of A549 and
H358 cells with stepwise incremental concentrations of
MTA (0.1–1.0 µM for A549; 0.5–10 µM for H358) as
previously reported31,39. Mesenchymal populations
(A549_EMT, H358_EMT), the cellular products emanat-
ing from mesenchymal reprogramming of A549 and H358
cells, were obtained after 3-month treatment (5 ng/ml for
A549; 2.5 ng/ml for H358) with TGF-β1 (AF-100-21C;
Peprotech, London, UK).
Cell viability assay and quantitative analysis of drug
synergy
Cells seeded in triplicate at 96-well plates (1000–1500
cells/well) were drugged 24 h later with various
compounds as indicated. Cell viability was determined
72 h post-treatment by the Acid Phosphatase Assay Kit
(ab83367; Abcam, Cambridge, UK) according to the
manufacturer’s protocol. Drug synergism was determined
by CompuSyn software, which is based on the median-
effect principle and the combination index–isobologram
theorem40. CompuSyn software generates fraction affec-
ted (Fa) and combination index (CI) values. CI < 1.0,
synergism; CI= 1.0, additive effects; CI > 1.0, antagonism.
Clonogenic assay
Cells seeded in triplicate at 103–104 cells/well (six-well
plates) were allowed to adhere overnight before treated
with various inhibitors or vehicle control for 24 h. The
treated cells were subsequently cultured in drug-free
medium for 7–14 days depending on growth rates, with
culture media replaced every 3–4 days. Surviving cells
were then ﬁxed with methanol (1%) and formaldehyde
(1%), visualized by staining with crystal violet (0.5% dis-
solved in 25% methanol). All experiments were performed
in three biological replicates and shown were repre-
sentative experiments.
Immunoblotting, immunoprecipitation, and
immunohistochemistry
Cell lysates were prepared using RIPA buffer (Cell
Signaling Technology, Hercules, CA, USA) containing
protease inhibitor cocktail and phosphatase inhibitors
(Santa Cruz, Dallas, TX, USA). Equal amounts of total
proteins were separated by SDS-PAGE (4561033; Bio-
Rad) and transferred to nitrocellulose membranes (170-
4156; Bio-Rad). After brief incubation with blocking
buffer (927-4000; Li-COR Biosciences, Bad Homburg,
Germany) at room temperature, the membranes were
blotted with primary antibodies (Supplementary Table
2) and anti-rabbit (926–32211) or anti-mouse (926-
68020) secondary antibodies (Promega, Madison, WI,
USA). Membrane-bound secondary antibodies were
visualized by the Odyssey Infrared Imaging System (Li-
COR Biosciences).
For immunoprecipitation, precleared cell lysates
(200 µg) and monoclonal anti-mouse HSP90 or anti-
rabbit PERK antibodies conjugated with Protein G
(37478 P) or Protein A agarose beads (9863 P) were mixed
by gentle rocking overnight at 4 °C. The beads were
washed ﬁve times with lysis buffer and bound proteins
were eluted by SDS sample buffer. Proteins in the pre-
cipitates were analyzed by immunoblotting.
For immunohistochemistry, tissues were ﬁxed in for-
malin, embedded in parafﬁn and cut into 4 μm sections.
Sections were stained with hematoxylin and eosin and
subjected to immunohistochemical staining following
standard protocols. Visualization was performed using the
Bond Polymer Reﬁne Detection kit (Leica Biosystems,
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Newcastle, UK) as instructed by the manufacturer. Images
were acquired using PANNORAMIC® whole slide scan-
ners and processed using CaseViewer (3DHISTECH Ltd,
Budapest, Hungary). In parallel, the staining intensity was
shown as blue (background), green (negative), yellow
(weak), orange (moderate), and red (strong) using the
gradient map visualization plugin within CaseViewer. The
following primary antibodies were used: Ki-67 (M7240;
Dako, Santa Clara, CA, USA), ZEB1 (HPA027524; Sigma),
and cleaved caspase 3 (9664; Cell Signaling Technology).
qRT-PCR
Total RNA was isolated and puriﬁed using RNeasy Mini
Kit (74106; Qiagen, Hilden, Germany). Complementary
DNA (cDNA) was synthesized by the High capacity
cDNA reverse transcription kit (4368814; Applied Bio-
systems, Foster City, CA, USA) according to the manu-
facturer’s instructions. Real-time PCR was performed in
triplicate on a 7500 Fast Real-Time PCR System (Applied
Biosystems) using TaqMan primer/probes (Applied Bio-
systems): HSPA5, Hs00607129_gH; ERN1,
Hs00980095_m1; EIF2AK3, Hs00984003_m1; ATF4,
Hs00909569_g1; DDIT3, Hs00358796_g1; BBC3,
Hs00248075_m1, and ATG7, Hs00893766_m1. GAPDH
(Hs02786624_g1) and ACTB (Hs01060665_g1) were used
as endogenous normalization controls.
Gene silencing by small interfering (siRNA) and short-
hairpin RNAs (shRNA)
Cells cultured in triplicate at 50–70% conﬂuency were
transfected using SiTran1.0 (TT300001; Origene Tech-
nologies, Rockville, MD, USA) according to the manu-
facturer’s protocol. EIF4E and EIF2AK3 were knocked
down by speciﬁc pooled siRNA duplexes (SR320018 and
SR306267; OriGene Technologies), with control siRNA
Duplex as a negative control.
Knockdown of MYC was achieved via lentiviral delivery
of MYC Human shRNA Plasmid Kit (TL311323; OriGene
Technologies). A scrambled shRNA was used as a control.
Lentiviral particles were generated and cells infected
according to the protocol from Broad Institute. The
supernatant containing lentiviruses was collected, ﬁltered
through 0.45 µm ﬁlters, and stored in aliquots at −80 °C,
or immediately used to infect recipient cells. After infec-
tion, cells were selected in puromycin (1.5 µg/ml) and
further passaged in culture for functional assays.
Secretion assay
5 × 106 cells seeded in 10-cm dishes were cultured in
FBS-free media for 6 h, with or without treated with 5 µg/
ml Brefeldin A (B6542; Sigma-Aldrich). Proteins in the
supernatant were precipitated by trichloroacetic acid,
separated by SDS-PAGE and visualized by Coomassie
blue staining.
Mining public databases (TCGA, CCLE, GDSC, and GEO),
GSEA, and gene ontology terms analysis
Transcriptomic and reverse phase protein array data of
cancer patients were obtained from the Cancer Genome
Atlas (TCGA). The gene expression and corresponding
survival data were extracted for correlation and prog-
nostic analysis using the corresponding packages in R
(“corrplot” and “Hmisc” packages for correlation analysis;
“maxstat”, “survival”, and “survminer” packages for
prognostic analysis). Analysis of the enriched biological
pathway, process, and molecular function from Gene
Ontology, as well as gene interaction map, were per-
formed using Funrich software41. The expression data and
drug sensitivity for cancer cell lines were obtained from
the Cancer Cell Line Encyclopedia (CCLE)42 and Geno-
mics of Drug Sensitivity in Cancer (GDSC)43, respectively.
Transcriptomic data of KRAS-dependent and -indepen-
dent cancer cell lines (GSE15126)2, matched melanoma
pre- and post-treated with MAPK inhibitors
(GSE65185)15 were downloaded from the Gene Expres-
sion Omnibus (GEO) database44. Gene set enrichment
analysis (GSEA) was performed using GSEA software45.
EMT and UPR gene signatures
The EMT status of tumors and cell lines was deter-
mined by the EMT gene signature18, scored as the sum of
a mesenchymal gene set (FN1+VIM+ ZEB1+ ZEB2+
TWIST1+ TWIST2+ SNAI1+ SNAI2+CDH2) minus
that of epithelial genes (CLDN4+CLDN7+ TJP3+
MUC1+CDH1). The UPR gene signature was calculated
using the sum of gene expression of MMP11, FN1,
METRN, BGN, SLC7A5, SPP1, CREB3L1, HIST1H1C,
COL5A2, ARNT2, COL1A2, TMED3, MTHFD2, SLC2A6,
IER3+CDH11, CTSD, SLC20A1, PDIA4, COL12A1,
ECM1, MAGED2 and PTRH1 as previously described46.
Patient samples
Experiments with surgically resected tumor specimens
from lung cancer patients (patient #1, 57-year-old female,
lung adenocarcinoma; patient #2, 67-year-old male,
KRAS-mutant lung adenocarcinoma) were approved by
the institutional review board, with informed consent
obtained from all patients as per protocol.
Animal studies
All mouse experiments approved by ethics committee
were performed in accordance with institutional regula-
tions governing animal care. Age- and gender-matched
NSG (NOD-SCID IL2Rγnull) mice were used for animal
experiments with human cell lines and PDXs. For H358
xenografts, tumor cells mixed with Matrigel (356231;
Corning) were subcutaneously inoculated in left and right
ﬂanks. For the PDX model, tumor tissues were cut into
small pieces (5 µm × 5 µm) and inserted into a
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subcutaneous pocket. Treatment was initiated when
tumors were palpable and drugs were prepared in the
following solvent: onalespib (2% DMSO+ 30% PEG 300
in H2O) and trametinib (4% DMSO in Corn Oil). Tra-
metinib (0.3 mg/kg for H358 xenografts, 0.5 mg/kg for
PDX) was administered 5 days/week (p.o.), and onalespib
(15 mg/kg for H358 xenografts and 30 mg/kg for PDX)
twice/week (i.p.). Tumor size/volume was calculated by
the formula: (D × d2)/2, where “D” refers to the long
tumor diameter and “d” the short one.
Ex vivo organotypic culture
Ex vivo organotypic culture and treatment were pro-
cessed as previously described39,47. In brief, freshly
explanted PDX tumors were mounted on agarose, soaked
in ice-cold sterile phosphate-buffered saline containing
antibiotic/antimycotic, and cut into slices (300–500 μM)
by Vibratome VT1200 (Leica Biosystems). Tissue slices
were placed in ultra-low attachment plates (3471; Corning
Incorporated, Corning, NY, USA) and covered by Dul-
becco's modiﬁed Eagle's medium medium supplemented
with 20% FBS and 1% penicillin/streptomycin solution.
After overnight culturing at 37 °C in a humid atmosphere
with 5% CO2 and 95% air, drug treatment was initiated
and lasted for up to 72 h.
Statistical analysis
Data were presented as mean ± s.d., with the indicated
sample size (n) representing biological replicates. Data
analysis was performed by GraphPad Prism 7 (GraphPad
Software, Inc., San Diego, CA, USA). Group size was
determined based on preliminary experiments but no
statistical method was used to predetermine sample size.
Group allocation was performed in a blinded manner. All
samples that met proper experimental conditions were
included in the analysis. Gene expression and survival
data derived from the public database, as well as corre-
lation coefﬁcient (Pearson and Spearman), were analyzed
using R (version 3.4.3). For survival analysis, patients were
grouped by gene expression, where “high” and “low”
expression groups were stratiﬁed by the optimal cutoff
value. Statistical signiﬁcance was determined by one-way/
two-way analysis of variance (ANOVA), Bonferroni’s
multiple comparison test, and Student’s t-test using
GraphPad Prism 7, unless otherwise indicated. P < 0.05
was considered statistically signiﬁcant.
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